Brokerages Set Adaptive Biotechnologies Corporation (NASDAQ:ADPT) PT at $17.11

Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) have earned a consensus recommendation of “Moderate Buy” from the eleven analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and nine have given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $17.1111.

A number of equities research analysts recently weighed in on ADPT shares. Piper Sandler upped their price target on Adaptive Biotechnologies from $15.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, October 15th. BTIG Research upped their target price on Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Guggenheim initiated coverage on Adaptive Biotechnologies in a research report on Tuesday, September 30th. They issued a “buy” rating and a $20.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Adaptive Biotechnologies from $17.00 to $20.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th.

Adaptive Biotechnologies Stock Performance

NASDAQ:ADPT opened at $18.26 on Friday. Adaptive Biotechnologies has a 1 year low of $5.97 and a 1 year high of $20.76. The stock has a fifty day moving average price of $16.47 and a two-hundred day moving average price of $14.37. The stock has a market capitalization of $2.79 billion, a price-to-earnings ratio of -33.81 and a beta of 2.18.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.01. Adaptive Biotechnologies had a negative net margin of 31.50% and a negative return on equity of 58.40%. The firm had revenue of $93.97 million during the quarter, compared to analysts’ expectations of $58.76 million. During the same quarter last year, the business earned ($0.22) earnings per share. The business’s revenue for the quarter was up 102.4% compared to the same quarter last year. On average, analysts predict that Adaptive Biotechnologies will post -0.92 EPS for the current year.

Insiders Place Their Bets

In other news, insider Francis Lo sold 3,125 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $16.08, for a total transaction of $50,250.00. Following the completion of the transaction, the insider directly owned 315,978 shares of the company’s stock, valued at $5,080,926.24. This trade represents a 0.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Sharon Benzeno sold 12,604 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $16.85, for a total value of $212,377.40. Following the completion of the sale, the insider directly owned 296,791 shares in the company, valued at approximately $5,000,928.35. The trade was a 4.07% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 1,358,650 shares of company stock valued at $23,122,398. Corporate insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ADPT. Sound Income Strategies LLC acquired a new position in shares of Adaptive Biotechnologies in the third quarter valued at approximately $30,000. Smartleaf Asset Management LLC grew its stake in Adaptive Biotechnologies by 593.5% in the 3rd quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company’s stock worth $59,000 after acquiring an additional 3,371 shares during the period. Caxton Associates LLP acquired a new position in Adaptive Biotechnologies in the 1st quarter valued at $93,000. Quadrant Capital Group LLC purchased a new position in shares of Adaptive Biotechnologies during the 3rd quarter worth $133,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Adaptive Biotechnologies during the second quarter worth $134,000. 99.17% of the stock is currently owned by hedge funds and other institutional investors.

Adaptive Biotechnologies News Roundup

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Total revenue and MRD outperformance — Adaptive reported preliminary Q4 revenue of about $72M and FY revenue of ~$277M, +51% and +55% vs. 2024, with MRD revenue ~ $62M (Q4) and ~$212M (FY). This substantial top‑line beat is the primary driver behind the stock move. Globe Newswire release
• Positive Sentiment: Guidance revision — the company updated Q4 and FY 2025 revenue guidance to ~$72M (Q4) and ~$277M (FY), both above Wall Street consensus, signaling stronger demand and execution. (See preliminary results above.)
• Positive Sentiment: Volume and product adoption — clonoSEQ test volume rose ~43% in Q4 (~30k tests) and ~39% for the year (~105.6k tests), indicating accelerating commercial adoption and recurring revenue potential. QuiverQuant summary
• Neutral Sentiment: Analyst backdrop and technicals — multiple recent buy/overweight ratings and a median price target near $20 provide support; the stock is trading above its 50‑ and 200‑day moving averages and also saw elevated intraday volume relative to its average, which amplifies moves.
• Neutral Sentiment: Short interest data appears unreliable — one feed flagged a “significant increase” but reported zero shares and NaN changes; treat short‑interest signals with caution until clean data is available.
• Negative Sentiment: Preliminary and unaudited results — management stresses these figures are unaudited and subject to change during year‑end close and audit, which introduces execution and disclosure risk that could reverse sentiment at final release. Globe Newswire release
• Negative Sentiment: Insider selling and expense opacity — public records show substantial insider sales over the past six months and the preliminary release did not disclose expense or final profitability metrics, leaving uncertainty on near‑term EPS trends and dilution risk. QuiverQuant summary

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.